Translational Research Core

转化研究核心

• 批准号: 10019346
• 负责人: Wayne M. Yokoyama
• 金额: $ 25.93万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10019346
• 关键词: African American; Animal Model; Antibodies; Archives; Asians; Award; Bioinformatics; Biological Specimen Banks; Cell model; Clinical; Clinical Data; Collection; Communities; Custom; Cytometry; Data Management Resources; Databases; Development; Enrollment; Future; Genetic; Genomics; Goals; Grant; Human Resources; Image; Immunologic Monitoring; Immunophenotyping; Infrastructure; Institutional Review Boards; Link; Metals; Outcome Measure; Patients; Process; Protocols documentation; Publications; Research; Research Personnel; Resources; Rheumatism; Rheumatoid Arthritis; Secure; Specimen; Technology; Time; Tissues; Training; Translating; Translational Research; Underrepresented Minority; Universities; Validation; Washington; Work; arthritis registry; base; biobank; bioinformatics tool; design; disease registry; expedited review; genomic data; human genomics; lupus registry; member; next generation sequencing; patient population; recruit; research and development; single cell sequencing; translational study

TRANSLATIONAL RESEARCH CORE ABSTRACT The overarching goal for the Translational Research Core is to promote, facilitate and accelerate translational science by providing the infrastructure, training and resources to support the investigators of Washington University Rheumatic Diseases Research Resource-based Center (WU-RDRRC) in their research endeavors. The highly trained TRC team will work closely with WU-RDRRC members in the design of clinical/translational studies, aid in the development of research protocols, help navigate institutional review board (IRB) requirements, assist in the collection or use of biospecimens, and facilitate access to high quality downstream analysis using genomics, bioinformatics, or immunophenotyping. In brief, the TRC team will guide investigators from concept development to genomic discovery with the ultimate goal of disseminating and/or translating the findings to practice. Towards these goals we will pursue the following Aims: 1. Develop an integrated rheumatic diseases Registry and biospecimens Repository (Biobank) that can be searched/maintained through electronic biomedical data management systems, allowing for the annotation, tracking, and sharing of tissue and databases. The Biobank maintains i) an open IRB protocol, allowing the broad collection of biospecimens linked to clinical data; ii) trained personnel to maintain IRB protocols and assist investigators in the submission of amended protocols for expedited review, recruit/enroll patients, collect/process specimens; iii) best biobanking practices for the archival of high quality biospecimens to be used in the initial or future studies by WU-RDRRC members. 2. Provide a Genomics & Bioinformatics Facility (GBF) powered by the most up-to-date Next-Generation Sequencing (NGS) technologies, including single cell sequencing, and sophisticated bioinformatics tools to enhance the secure use and analysis of human genomics data. 3. Provide an ImmunoMonitoring Facility (IMF) that offers training and access to mass cytometry as well as several panels of validated custom-designed metal-conjugated CyTOF-ready antibodies and tetramers that are currently not available commercially.

翻译研究核心摘要 翻译研究核心的首要目标是促进、促进和加速翻译 科学通过提供基础设施、培训和资源来支持华盛顿的调查人员 大学风湿病研究资源型中心(WU-RDRRC)的研究工作。 训练有素的TRC团队将与WU-RDRRC成员在临床/翻译设计方面密切合作 研究，帮助制定研究方案，帮助导航机构审查委员会(IRB) 要求，协助收集或使用生物检疫制剂，并便利获得高质量的下游产品 使用基因组学、生物信息学或免疫表型进行分析。简而言之，真相与和解委员会团队将指导 研究人员从概念开发到基因组发现，最终目的是传播 和/或将研究结果转化为实践。为了实现这些目标，我们将实现以下目标： 1.开发综合风湿病登记和生物检疫库(Biobank)，可以 通过电子生物医学数据管理系统进行搜索/维护，允许 组织和数据库的注释、跟踪和共享。生物库主张：1)开放的内部审查委员会 议定书，允许广泛收集与临床数据有关的生物标本；二)培训人员 维护IRB方案并协助调查人员提交修改后的方案以加快 审查、招募/登记患者、收集/处理标本；iii)档案的最佳生物库做法 WU-RDRRC成员将在最初或未来的研究中使用的高质量生物检疫剂。 2.提供基因组学和生物信息学设施(GBF)，由最新的下一代 测序(NGS)技术，包括单细胞测序和尖端生物信息学 加强人类基因组数据安全使用和分析的工具。 3.提供免疫监测设施(IMF)，该机构还提供培训和使用质量细胞分析技术 作为几组经过验证的定制设计的金属偶联细胞因子就绪抗体和 目前还没有商业化的四聚体。